MyMD Pharmaceuticals Files 8-K Amendment
Ticker: QCLS · Form: 8-K/A · Filed: Jun 20, 2024 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Mymd Pharmaceuticals, Inc. (QCLS) |
| Form Type | 8-K/A |
| Filed Date | Jun 20, 2024 |
| Risk Level | medium |
| Pages | 8 |
| Reading Time | 10 min |
| Key Dollar Amounts | $0.001, $1,000, $1.816, $8.9 million, $5.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, material-agreement
TL;DR
MyMD amended its 8-K filing for a May 20th agreement - details TBD.
AI Summary
MyMD Pharmaceuticals, Inc. filed an amendment (8-K/A) on June 20, 2024, to a previous filing concerning a material definitive agreement entered into on May 20, 2024. The amendment does not provide specific details about the agreement itself but serves to correct or supplement information previously reported.
Why It Matters
This filing indicates a correction or addition to a previously disclosed material agreement, which could impact the understanding of the company's contractual obligations or strategic partnerships.
Risk Assessment
Risk Level: medium — Amendments to material definitive agreements can signal changes or clarifications that may affect the company's financial or operational standing.
Key Numbers
- 001-36268 — SEC File Number (Identifies the company's filing with the SEC.)
Key Players & Entities
- MyMD Pharmaceuticals, Inc. (company) — Registrant
- May 20, 2024 (date) — Date of earliest event reported
- June 20, 2024 (date) — Filing date of the amendment
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific information is being amended in the 8-K filing?
The filing does not specify the exact nature of the amendment, only that it is an amendment to a previously filed 8-K regarding a material definitive agreement.
What was the original date of the material definitive agreement?
The original material definitive agreement was entered into on May 20, 2024.
When was this amendment filed with the SEC?
This amendment (8-K/A) was filed on June 20, 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at 855 N. Wolfe Street, Suite 623, Baltimore, MD 21205.
What was the former name of MyMD Pharmaceuticals, Inc.?
The company was formerly known as Akers Biosciences, Inc.
Filing Stats: 2,474 words · 10 min read · ~8 pages · Grade level 17.5 · Accepted 2024-06-20 17:20:15
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share MYMD The Nasdaq Capital M
- $1,000 — $0.001 per share and a stated value of $1,000 per share, initially convertible into u
- $1.816 — Common Stock") at a conversion price of $1.816 per share (the "Series G Preferred Stoc
- $8.9 million — G Private Placement are expected to be $8.9 million and the aggregate gross proceeds from t
- $5.0 million — -1 Private Placement are expected to be $5.0 million. The Company expects to use the net pro
- $5.448 — e of the Common Stock equals or exceeds $5.448 per share (subject to adjustment for st
- $3,000,000 — on Stock exceeds three million dollars ($3,000,000) per trading day during the same period
- $2.253 — lculated assuming a conversion price of $2.253 per share, which was the Minimum Price
Filing Documents
- form8-ka.htm (8-K/A) — 56KB
- 0001493152-24-024548.txt ( ) — 231KB
- mymd-20240520.xsd (EX-101.SCH) — 3KB
- mymd-20240520_lab.xml (EX-101.LAB) — 33KB
- mymd-20240520_pre.xml (EX-101.PRE) — 22KB
- form8-ka_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYMD PHARMACEUTICALS, INC. Date: June 20, 2024 By: /s/ Mitchell Glass Name: Mitchell Glass Title: President and Chief Medical Officer